ProBioGen AG

69 articles about ProBioGen AG

• 

  BioSpace Global Roundup, Oct. 3

  10/3/2019

  Companies from across the globe share information on their business and pipelines.

• ProBioGen and Ceva Santé Animale Sign an Exclusive License Agreement to Produce Vectorised Poultry Vaccines Using AGE1.CR® Production Technology

  10/1/2019

  ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.

• 

  BioSpace Global Roundup, Sept. 12

  9/12/2019

  Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.

• ProBioGen Licenses GlymaxX® Technology to Bayer

  9/10/2019

  ProBioGen AG announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.

• ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

  5/23/2019

  ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a services and license agreement with Abcuro, Inc.

• ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform

  5/15/2019

  ProBioGen AG, a premier German service & technology provider for complex biologics and Vaccitech, Ltd., a spin-out company from the University of Oxford’s Jenner Institute, one of the most renowned vaccine research centers in the world, today jointly announced signing a license agreement

• ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

  1/3/2019

  Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology

• ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

  11/6/2018

  ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.

• ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project

  7/10/2018

  ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.

• ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

  6/26/2018

  ProBioGen AG and Nouscom AG, today jointly announced signing a license agreement.

• ProBioGen and TEVA Sign License Agreement on Human Artificial Lymph Node Technology

  2/7/2018

  The unique human Artificial Lymph Node model was developed by ProBioGen as superior 3D-micro-organoid model for analyzing substance effects on the human immune system in vitro.

• Chiome Bioscience Selects ProBioGen AG For GlymaxX Antibody Manufacturing Program

  10/6/2017

• ProBioGen AG Grants A License For Human Lymph Node Technology To TissUse For Multi-Organ-Chip Applications

  6/15/2017

• Merus Signs Commercial Multi-Product License For ProBioGen AG’s Glymaxx ADCC Enhancement Technology

  6/1/2016

• ProBioGen AG Will License GlymaxX To Thermo Fisher Scientific For Use In Developing Allergy Diagnostics

  5/18/2016

• ProBioGen AG And EUCODIS Bioscience Sign Agreement To Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

  4/19/2016

• ProBioGen AG In Biosimilar Deal With Bio Farma Indonesia

  10/28/2015

• Zymeworks Contracts ProBioGen AG For Bi-specific GlymaxX Antibody Cell Line Development

  10/14/2015

• ProBioGen AG Inks Another Commercial Glymaxx License And Contract Manufacturing Service Agreement On Immuno-Oncology Antibody

  10/1/2015

• Anti-Ebola MVA Vaccine Produced On ProBioGen AG’s Avian AGE1.CR Cell Line Platform In Clinical Trials

  6/2/2015